Follow-up on corrections·May 30, 2024

Licensing Program Analyst (LPA) Jessica Cho continued an unannounced Case-Management visit after delivering the findings in connection to Complaint Control Number: 22-AS-20240321121345 . The purpose of this visit is to issue a deficiency that was discovered during the investigation mentioned above. LPA explained the reason for the visit to Administrator Aurelia Olais and Resident Care Director Paula Tanglao . During the investigation, it was discovered that Resident #1 (R1) presented an unknown rash that was alleged as scabies which spread throughout R1's body. Although the facility requested a skin test to R1's hospice agency, facility failed to pursue a skin test (or seek medical care) to ensure that the resident's needs are being met. Per record review, R1 was prescribed Ivermectin and Permethrin which is commonly used to treat scabies. The skin rash cleared after the treatments. Therefore, based on the interviews which were conducted and the records that were reviewed, the preponderance of evidence standard has been met. A deficiency is being cited as per the Title 22, Division 6, Chapter 8 of the California Code of Regulations. Please see the attached LIC809-D. An exit interview was conducted with Administrator Aurelia Olais and Resident Care Director Paula Tanglao, and a copy of this report including the LIC809-D were provided at the end of the visit.